All Stories

  1. Statins use and cancer: an update

    Article • Future Oncology, June 2018, Future Medicine

    Dr Jacek Bil

  2. Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction

    Article • Current Pharmaceutical Design, April 2018, Bentham Science Publishers

    Dr Jacek Bil

  3. Calcium–phosphate metabolism disturbances in patients with significant mitral regurgitation

    Article • Polish Archives of Internal Medicine, January 2018, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

    Dr Jacek Bil

  4. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience

    Article • Cardiology Journal, December 2017, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  5. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up

    Article • The International Journal of Cardiovascular Imaging, September 2017, Springer Science + Business Media

    Dr Jacek Bil

  6. Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model

    Article • Cardiovascular Therapeutics, July 2017, Wiley

    Dr Jacek Bil

  7. Platelet distribution width as the prognostic marker in coronary bifurcation treatment

    Article • European Journal of Clinical Investigation, June 2017, Wiley

    Dr Jacek Bil

  8. BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent

    Article • Expert Review of Medical Devices, April 2017, Taylor & Francis

    Dr Jacek Bil

  9. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry

    Article • EuroIntervention, November 2016, Europa Digital & Publishing

    Dr Jacek Bil

  10. Prognozowanie wzrostu stężenia troponiny na podstawie elektrokardiogramu wewnątrzwieńcowego wykonanego w trakcie przezskórnej interwencji wieńcowej w obrębie rozwidlenia tętnic wieńcowych (dane z badania COronary SIde Branch Residual IschemiA and COllater

    Article • Kardiologia Polska, September 2016, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  11. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review

    Article • Advances in Medical Sciences, September 2016, Elsevier

    Dr Jacek Bil

  12. Bioresorbable vascular scaffolds—what does the future bring?

    Article • Journal of Thoracic Disease, August 2016, AME Publishing Company

    Dr Jacek Bil

  13. Wykorzystanie stentów bioresorbowalnych Absorb BVS® u pacjentów ze stabilną chorobą wieńcową: ocena skuteczności i bezpieczeństwa leczenia hybrydowego stentów bioresorbowalnych i stentów uwalniających lek

    Article • Kardiologia Polska, July 2016, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  14. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies

    Article • The International Journal of Cardiovascular Imaging, June 2016, Springer Science + Business Media

    Dr Jacek Bil

  15. Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis

    Article • BMC Cardiovascular Disorders, November 2015, Springer Science + Business Media

    Dr Jacek Bil

  16. Coronary spasm revascularized with a bioresorbable vascular scaffold

    Article • Coronary Artery Disease, November 2015, Wolters Kluwer Health

    Dr Jacek Bil

  17. The BiOSS stent

    Article • EuroIntervention, May 2015, Europa Digital & Publishing

    Dr Jacek Bil

  18. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial

    Article • Canadian Journal of Cardiology, May 2015, Elsevier

    Dr Jacek Bil

  19. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins

    Article • Blood Cancer Journal, April 2015, Nature

    Dr Jacek Bil

  20. First-in-Man Study of Dedicated Bifurcation Sirolimus-eluting Stent: 12-month Results of BiOSS LIM® Registry

    Article • Journal of Interventional Cardiology, February 2015, Wiley

    Dr Jacek Bil

  21. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies

    Article • mAbs, September 2014, Taylor & Francis

    Dr Jacek Bil

  22. Dedicated Bifurcation Paclitaxel-Eluting Stent BiOSS Expert® in the Treatment of Distal Left Main Stem Stenosis

    Article • Journal of Interventional Cardiology, April 2014, Wiley

    Dr Jacek Bil

  23. Trzy-miesięczne wyniki rejestru nowego stentu dedykowanego do leczenia bifurkacji uwalniającego sirolimus BiOSS LIM C

    Article • Kardiologia Polska, January 2014, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  24. Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR

    Article • The International Journal of Cardiovascular Imaging, September 2013, Springer Science + Business Media

    Dr Jacek Bil

  25. Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSS® stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study

    Article • The International Journal of Cardiovascular Imaging, July 2013, Springer Science + Business Media

    Dr Jacek Bil

  26. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study

    Article • Cardiology Journal, January 2013, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  27. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies

    Article • Cardiology Journal, January 2013, VM Media SP. zo.o VM Group SK

    Dr Jacek Bil

  28. Dedicated Bifurcation Drug-eluting Stent BiOSS® – A Novel Device for Coronary Bifurcation Treatment

    Article • Interventional Cardiology Reviews Research Resources, January 2013, Medical Media Communications, Ltd. T/A Radcliffe Cardiology

    Dr Jacek Bil

  29. Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity

    Article • Journal of Biological Chemistry, July 2012, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Jacek Bil

  30. Statins Impair Glucose Uptake in Tumor Cells

    Article • Neoplasia, April 2012, Elsevier

    Dr Jacek Bil

  31. Antitumor effects of the combination of cholesterol reducing drugs

    Article • Oncology Reports, April 2011, Spandidos Publications

    Dr Jacek Bil

  32. Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application

    Article • Oncology Reports, March 2011, Spandidos Publications

    Dr Jacek Bil

  33. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies

    Article • Frontiers in Bioscience, January 2011, Frontiers in Bioscience

    Dr Jacek Bil

  34. Proteolytic pathways involved in modulation of CD20 levels

    Article • Autophagy, August 2010, Taylor & Francis

    Dr Jacek Bil

  35. Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

    Article • American Journal Of Pathology, June 2010, Elsevier

    Dr Jacek Bil, Dr Piotr Abramczyk

  36. Photodynamic therapy-driven induction of suicide cytosine deaminase gene

    Article • Cancer Letters, April 2010, Elsevier

    Dr Jacek Bil

  37. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

    Article • Blood, March 2010, American Society of Hematology

    Dr Jacek Bil

  38. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro

    Article • Cancer Letters, February 2010, Elsevier

    Dr Jacek Bil

  39. Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response

    Article • Cancer Research, May 2009, American Association for Cancer Research (AACR)

    Dr Jacek Bil, Prof Michael R Hamblin

  40. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice

    Article • BMC Cancer, July 2008, Springer Science + Business Media

    Dr Tomasz A Stoklosa, Dr Jacek Bil

  41. Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20

    Article • PLoS Medicine, March 2008, PLOS

    Dr Tomasz A Stoklosa, Dr Jacek Bil